GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » 5-Year ROIIC %

AVEO Pharmaceuticals (AVEO Pharmaceuticals) 5-Year ROIIC % : -1,206.34% (As of Dec. 2021)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. AVEO Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2021 was -1,206.34%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for AVEO Pharmaceuticals's 5-Year ROIIC % or its related term are showing as below:

AVEO's 5-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -19.48 vs AVEO: -1206.34

AVEO Pharmaceuticals 5-Year ROIIC % Historical Data

The historical data trend for AVEO Pharmaceuticals's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals 5-Year ROIIC % Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's 5-Year ROIIC %

For the Biotechnology subindustry, AVEO Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's 5-Year ROIIC % falls into.



AVEO Pharmaceuticals 5-Year ROIIC % Calculation

AVEO Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2021 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -49.554 (Dec. 2021) - -29.5046934 (Dec. 2016) )/( 6.157 (Dec. 2021) - 4.495 (Dec. 2016) )
=-20.0493066/1.662
=-1,206.34%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


AVEO Pharmaceuticals  (NAS:AVEO) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


AVEO Pharmaceuticals 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus

LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

By Value_Insider Value_Insider 10-18-2022